Use of Decision Models in the Development of Evidence-Based Clinical Preventive Services Recommendations: Methods of the U.S. Preventive Services Task Force

The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services. Decision modeling is useful when clinical questions remain about how to target an empirically established clinical preventive service at the individual or program level or when complex determinations of magnitude of net benefit, overall or among important subpopulations, are required. Before deciding whether to use decision modeling, the USPSTF assesses whether the benefits and harms of the preventive service have been established empirically, assesses whether there are key issues about applicability or implementation that modeling could address, and then defines the decision problem and key questions to address through modeling. Decision analyses conducted for the USPSTF are expected to follow best practices for modeling. For chosen topics, the USPSTF assesses the strengths and limitations of the systematically reviewed evidence and the modeling analyses and integrates the results of each to make preventive service recommendations.

**RATIONALE FOR USE OF DECISION MODELS**

Modeling offers the potential to address questions that have not been or cannot be answered by clinical trials (6). Modeling is a potentially useful complement to the systematic evidence reviews prepared for the recommendations. Unlike epidemiologic models that project the course of disease or seek to make inferences about the cause of disease, decision models assess the benefits and harms of intervention strategies by examining the effect of specific interventions. The USPSTF has used decision models to aid in the development of recommendations for 4 cancer screening topics (colorectal, breast, cervical, and lung cancer) (1–4) and 1 preventive medication topic (aspirin to prevent cardiovascular disease and colorectal cancer [CRC]) (5). For these services, decision models allowed the USPSTF to consider the lifetime effect of different screening programs (for example, combinations of screening methods and intervals for colorectal or cervical cancer) in specific populations (that is, various ages for starting or stopping screening for breast, cervical, colorectal, and lung cancer) (Table 3).

This article outlines the history and rationale for the USPSTF’s use of decision models and articulates its current approach to using these models. The USPSTF developed this approach from 2014 to 2015 to establish guidance on determining topics for which decision modeling would be useful in making USPSTF recommendation statements.
USPSTF to assess appropriate starting or stopping ages; compare alternative intervals of preventive service delivery; compare alternative technologies, such as different screening tests; assess the effect of a new test in an established screening program; quantify potential net benefit more precisely or specifically than can be accomplished based on the systematic evidence review alone; extend the time horizon beyond that available from outcomes studies; assess net benefit for populations and groups at higher or lower risk for benefits or harms; assess net benefit stratified by sex or other clinically important demographic characteristics, such as race/ethnicity or comorbid conditions; and assess uncertainty in estimates of benefits, harms, and net benefits (6–8).

Of particular importance, models can enable the USPSTF to integrate evidence across the analytic framework and key questions in the accompanying systematic review. For example, the model for the USPSTF recommendations on aspirin for the primary prevention of cardiovascular disease and CRC helped integrate evidence across key questions from 3 systematic evidence reviews. The reviews discussed the effect of aspirin on cardiovascular and total mortality, the effect of aspirin in reducing the incidence of CRC, and the harms of aspirin (9).

Whether the USPSTF uses models for a preventive service depends on the service under consideration, the state of existing empirical evidence, the suitability of models for specific purposes, and the resources available.

Table 1. What the USPSTF Grades Mean and Suggestions for Practice

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
<th>Suggestions for Practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>The USPSTF recommends the service. There is high certainty that the net benefit is substantial.</td>
<td>Offer/provide this service.</td>
</tr>
<tr>
<td>B</td>
<td>The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.</td>
<td>Offer/provide this service.</td>
</tr>
<tr>
<td>C</td>
<td>The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small.</td>
<td>Offer/provide this service for selected patients depending on individual circumstances.</td>
</tr>
<tr>
<td>D</td>
<td>The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.</td>
<td>Discourage the use of this service.</td>
</tr>
<tr>
<td>I statement</td>
<td>The current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.</td>
<td>Read the Clinical Considerations section of the USPSTF Recommendation Statement. If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.</td>
</tr>
</tbody>
</table>

USPSTF = U.S. Preventive Services Task Force.

Table 2. USPSTF Levels of Certainty Regarding Net Benefit

<table>
<thead>
<tr>
<th>Level of Certainty*</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the results of future studies.</td>
</tr>
<tr>
<td>Moderate</td>
<td>The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as: the number, size, or quality of individual studies; inconsistency of findings across individual studies; limited generalizability of findings to routine primary care practice; and lack of coherence in the chain of evidence. As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion.</td>
</tr>
<tr>
<td>Low</td>
<td>The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of: the limited number or size of studies; important flaws in study design or methods; inconsistency of findings across individual studies; gaps in the chain of evidence; findings that are not generalizable to routine primary care practice; and a lack of information on important health outcomes. More information may allow an estimation of effects on health outcomes.</td>
</tr>
</tbody>
</table>

USPSTF = U.S. Preventive Services Task Force.

* The USPSTF defines certainty as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as benefit minus harm of the preventive service as implemented in a general primary care population. The USPSTF assigns a certainty level on the basis of the nature of the overall evidence available to assess the net benefit of a preventive service.
direct evidence of benefit in clinical trials, at least for some populations, or indirect evidence of benefit estab-
lished through the linkages in the analytic framework (Figure 1) based on the systematic evidence re-
view (10). Direct evidence comes from a clinical trial that evaluates the preventive service and assesses
health outcomes of importance to patients, such as disease-specific mortality, total mortality, or quality of
life (Figure 1, step 1). An example is the NLST (National Lung Screening Trial) (11), which showed that screening
with low-dose computed tomography (CT) reduced lung cancer-specific mortality by 16%. Indirect evidence
comprises evidence for a series of linkages that connect the intervention to health outcomes, with ade-
quate evidence that the intervention changes health outcomes (Figure 1, steps 2 to 4). For example, the
effect of HIV screening on mortality has not been as-
sumed directly in clinical trials, but there is evidence
that HIV can be diagnosed accurately and that early
treatment reduces mortality and HIV transmission (12).
In contrast, a recent assessment of screening for thyroid
dysfunction found that the evidence was insufficient to
assess benefits and harms; therefore, this topic would
not be a candidate for modeling (13).

Even with adequate direct or indirect evidence, the
USPSTF uses modeling only if there are important con-
siderations or uncertainty that empirical evidence has
not addressed. Decision modeling is primarily war-
ranted when there are outstanding clinical questions
about how to best target an empirically established
clinical preventive service at the individual and pro-
gram level. In addition, modeling can help the USPSTF
assess the net benefit of a preventive service when there are established benefits and harms.

For most A and B recommendations, the primary evidence is sufficient for the USPSTF to understand the

---

Table 3. Purposes of Decision Modeling for USPSTF Topics

<table>
<thead>
<tr>
<th>Previous Recommendation</th>
<th>Purpose of Using Model-Based Analyses</th>
<th>Most Recent Recommendation</th>
<th>Incorporation of Modeling Results in Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Colorectal cancer</strong></td>
<td>Assess screening method (e.g., colonoscopy, fecal occult blood test, and sigmoidoscopy)</td>
<td>2016 A recommendation (C for ages 76-85 y)</td>
<td>Modeling identified sigmoidoscopy alone as the strategy with the least benefits. Caution added to recommendations.</td>
</tr>
<tr>
<td>2008 A recommendation</td>
<td>Assess ages at which to begin and end screening Assess screening interval Assess potential benefits</td>
<td>2016 B recommendation (C for ages 40-49 y)</td>
<td>Modeling was useful in understanding benefits and harms of different screening intervals and starting ages.</td>
</tr>
<tr>
<td><strong>Breast cancer</strong></td>
<td>Assess ages at which to begin and end screening Assess screening interval Assess potential benefits</td>
<td>2012 A recommendation (D for ages &lt;21 y and &gt;65 y)</td>
<td>Modeling was useful in comparing alternative screening strategies; it helped to identify cotesting with the human papillomavirus test every 5 y as an effective option.</td>
</tr>
<tr>
<td>2009 B recommendation</td>
<td>Assess screening interval Assess ages at which to begin and end screening Assess screening method (human papillomavirus testing, human papillomavirus and cytology testing, and liquid-based vs. conventional cytology)</td>
<td>2013 B recommendation for adults aged 55-80 y with a 30-pack-year smoking history and who currently smoke or have quit within the past 15 y</td>
<td>Modeling informed choice of criteria for screening (starting and stopping ages, years of smoking, and years since last smoked).</td>
</tr>
<tr>
<td><strong>Cervical cancer</strong></td>
<td>Assess ages at which to begin and end screening Assess screening interval Assess potential benefits</td>
<td>2016 Modeling was useful in estimating net benefit by age and sex; it informed age stratification and corresponding grades.</td>
<td></td>
</tr>
<tr>
<td>2003 A recommendation</td>
<td>Assess screening interval Assess ages at which to begin and end screening Assess screening method (human papillomavirus testing, human papillomavirus and cytology testing, and liquid-based vs. conventional cytology)</td>
<td>2012 A recommendation (D for ages &lt;21 y and &gt;65 y)</td>
<td>Modeling was useful in comparing alternative screening strategies; it helped to identify cotesting with the human papillomavirus test every 5 y as an effective option.</td>
</tr>
<tr>
<td><strong>Lung cancer</strong></td>
<td>Assess ages at which to begin and end screening Assess screening interval Assess eligibility for smoking (pack-years of smoking history or years since quitting) Assess eligibility to stop smoking (years since quitting)</td>
<td>2013 B recommendation for adults aged 55-80 y with a 30-pack-year smoking history and who currently smoke or have quit within the past 15 y</td>
<td>Modeling informed choice of criteria for screening (starting and stopping ages, years of smoking, and years since last smoked).</td>
</tr>
<tr>
<td>2004 I statement</td>
<td>Assess ages at which to begin and end screening Assess screening interval Assess potential benefits</td>
<td>2016 Modeling was useful in estimating net benefit by age and sex; it informed age stratification and corresponding grades.</td>
<td></td>
</tr>
</tbody>
</table>

USPSTF = U.S. Preventive Services Task Force.
* New topic.
net benefit and develop a recommendation; thus, modeling is not necessary. For example, for the USPSTF recommendations on smoking cessation, the evidence for the link between smoking and harmful outcomes was strong, and the evidence for the usefulness of behavioral interventions alone or in combination with pharmacotherapy to improve achievement of smoking cessation was convincing. Because the key questions could be answered by the evidence review, modeling was not needed (14).

Prior decisions about using modeling for USPSTF topics have been made on a case-by-case basis. Because the number of topics for which modeling could be considered is expanding and resources for modeling are limited, the USPSTF determined that a more systematic approach for assessing when to use modeling as an adjunct to systematic review would be useful.

To help select and prioritize topics for modeling, the USPSTF developed a framework for deciding when and how it would incorporate decision modeling into the development of recommendations. This framework combines scientific considerations with process issues and also requires value judgments. The USPSTF proposed a set of 4 sequential questions to be answered in the early stages of planning when feasible, ideally during the research plan development phase. These questions attempt to quantify the appropriateness, focus, approach, and requirements of potentially incorporating a decision model with a systematic review for a specific topic. The process for addressing these questions is represented in Figure 2.

Addressing the 4 questions is intended to systematize the consideration of decision models and assist USPSTF leadership in prioritizing competing demands across its entire portfolio by determining when adding decision modeling to a review is both feasible and a high priority. A more detailed description of the approach is available in the USPSTF procedure manual (15).

Topics with existing USPSTF recommendations based on relatively current systematic reviews may have a reasonably concrete set of questions that trigger an early decision to use decision modeling. This is particularly common when decision models informed the previous recommendation. For new topics, or those for which the evidence base for the efficacy of a preventive service is only beginning to become clear, additional time will probably be required before the desirability of decision modeling can be determined (Figure 1, step 3). In most cases, some degree of simultaneous activity will require coordination between the decision modeling and systematic review teams.
Decision Modeling for USPSTF Recommendations

**Figure 2.** Overall process for determining whether to add decision modeling to a systematic review in preparing the evidence for USPSTF recommendation statements.

1. Has the overall benefit or harm of the preventive service been established? **No**
2. Are there key issues about the applicability or implementation of this recommendation that DM could address? **Yes**
3. Is there enough information to proceed with DM planning at this point? **No**
4. What is the decision problem to be addressed, and what key questions should the DM address? **Yes**

---

For topics for which modeling may be useful, an additional consideration is whether existing, published, model-based analyses are sufficient to address the needs of the USPSTF. Using existing analyses is faster and less expensive than commissioning new ones. However, identifying and evaluating existing models can be resource-intensive and may not yield a model that sufficiently answers questions of importance to the USPSTF. Commissioning new modeling enables the USPSTF to work with the modelers to better understand modeling results, ensure that the most current and applicable evidence is used, and evaluate questions that may not be addressed in the literature.

Decision modeling increases resource requirements for systematic reviewers and the modeling team. Coordinating systematic reviews and modeling to inform an evidence-based recommendation requires planning to ensure appropriate timing and integration as well as substantial investment to ensure consistency and clarity of results. Thus, modeling increases the resources required and may lengthen the time required to develop a recommendation.

The USPSTF leadership decides whether to use modeling for a topic after considering both the potential benefits of modeling and the available resources. Because modeling requires substantial additional resources and expertise, it is used selectively. Highest-priority topics include those for which prior recommendations used modeling and those for which there are important additional questions that can only be addressed by modeling. To date, such questions have been the comparison of alternative strategies for screening (for example, screening for CRC and lung cancer) and the estimation of net benefit (for example, the benefit and harms of aspirin use for the primary prevention of cardiovascular disease and CRC).

**Historical Incorporation of Decision Model Results in Recommendations**

The USPSTF considers modeling results as supplementary analyses to systematic evidence reviews. As noted, the USPSTF uses modeling analyses only if the primary evidence is sufficient to make a recommendation. In general, the grades for a recommendation (A, B, C, and D and the I statement) are based primarily on assessment of the evidence in the systematic review rather than modeling. In complex cases, however, modeling can be useful in estimating the magnitude of net benefit based on analyses of relative benefits and harms of alternative screening strategies (for example, sigmoidoscopy vs. colonoscopy for CRC screening), different starting and stopping ages, and different screening intervals (for example, lung cancer). During recommendation development, a small working group assigned to the topic works closely with the evidence review and modeling teams to develop key questions (which are publicly posted), discuss interim results, and iteratively refine the questions and analyses. The results of the final evidence synthesis from the systematic review and modeling results are presented to the entire USPSTF during the meeting in which the recommendation statement is deliberated.

In addressing how to incorporate modeling results, the USPSTF assesses how well the model captures both the benefits and harms of the intervention and the strength of the evidence that supports the model. The USPSTF gives more weight to modeling analyses when the models fully capture the relevant benefits and harms and the underlying evidence is adequate for the analysis being done. To make such assessments, the USPSTF considers the model’s structure, assumptions, and limitations. It also assesses the degree of concordance between the data and assumptions in the model and the systematic evidence review. For example, the modeling for the recommendations on CRC screening (1) suggested that screening before age 50 years may be beneficial (16). However, because there are few empirical data on screening in adults younger than 50 years, the USPSTF gave less weight to the model-based analysis of screening beginning before age 50 years.

The modeling analyses for lung cancer screening (17), CRC screening (16), and aspirin for primary prevention (9) are useful examples. The modeling analysis for lung cancer (17) evaluated 576 possible screening programs for such factors as different starting and stopping ages, history of smoking (in pack-years), and years since cessation of smoking (Figure 3). The NLST enrolled adults aged 55 to 74 years at entry who had at least 30 pack-years of smoking and had quit no more than 15 years before entry. The trial followed patients for up to 7 years and thus had some who were older...
than 75 years at completion. As shown in Figure 3, the strategy that used the NLST entry criteria was slightly off the solid line, indicating that one could obtain the same benefit with fewer CT scans or more benefit for the same number of CT scans with strategies that were slight variations of the NLST criteria. These analyses helped inform the USPSTF about which criteria to choose for screening. Ultimately, it recommended screening adults aged 55 to 80 years with 30 pack-years of smoking who had quit less than 15 years before, which is a strategy similar to that of the NLST but still on the efficient frontier.

The modeling analyses for CRC screening (16) assessed the relative benefits and harms of alternative strategies, including colonoscopy, fecal immunochemical testing, and sigmoidoscopy. The analyses helped the USPSTF assess which criteria to choose for screening. Ultimately, it recommended screening adults aged 55 to 80 years with 30 pack-years of smoking who had quit less than 15 years before, which is a strategy similar to that of the NLST but still on the efficient frontier.

The modeling analyses for aspirin use for the primary prevention of cardiovascular disease and CRC (9) integrated benefits from reduced cardiovascular disease and CRC incidence as well as the harms of aspirin use. The analyses showed that aspirin use provides greater net benefit for adults aged 50 to 59 years than those aged 60 to 69 years. For example, aspirin use in women aged 50 to 59 years with a 10-year risk for cardiovascular disease of 15% resulted in 33.4 life-years and 71.6 quality-adjusted life-years per 1000 women, whereas for women aged 60 to 69 years, the corresponding benefits were 1.7 life-years and 32.4 quality-adjusted life-years. Benefit is reduced in older adults because the risk for bleeding with aspirin increases with age and because they are less likely to benefit from reduced CRC incidence given that this effect takes at least 10 years to become evident. These analyses informed the USPSTF’s estimate of the magnitude of net benefit of aspirin use by age and were among several factors considered in assigning a grade.

The USPSTF methods work group is continuing to work on guidance about how to integrate model results and evidence reviews. As the USPSTF gains more experience with modeling, it expects to further modify and adjust its approach.

**METHODOLOGICAL CONSIDERATIONS**

The USPSTF expects its models to conform to recommended best practices (6, 7, 18–24). The population represented, intervention delivery and performance characteristics, adherence assumptions, choice of base case, and time horizon should fit the questions asked by the USPSTF and be clearly communicated to users of its recommendations. The USPSTF’s approach of conducting modeling in conjunction with a systematic evidence review allows for a coordinated effort that brings the rigor of the systematic evidence review to the estimation of key model parameters. The modeling results should highlight assumptions, limitations, and implications of uncertainty in the analyses.

When both models and evidence reviews are used to inform recommendations, the USPSTF and other users of these evidence synthesis products should understand...
Decision Modeling for USPSTF Recommendations

stand the consistency and differences in the methods and findings from the systematic review and the models. The USPSTF has identified several areas with the potential for difference. For example, the systematic evidence review evaluates efficacy (or effectiveness) over the duration of the clinical trials, whereas modeling studies often evaluate benefits over longer time horizons—perhaps the entire lifetime of persons who have the intervention or screening.

Coordination between the systematic review and modeling teams is important. Engaging modelers early in the scientific process can be useful (25, 26), but the most important questions for decision modeling can change (or do not become apparent) well into the systematic review process or after it is complete. If decision modeling is a high priority for a topic, the USPSTF must determine when it will be possible to define the objective and key questions for decision modeling (18, 26). Systematic review results for some key questions may provide needed values or validation targets. However, in many cases, the systematic evidence review will not provide values that can be input directly into the models, and modeling teams may need to do their own literature review.

CONCLUSIONS AND FUTURE DIRECTIONS

Decision modeling has been useful as an adjunct to systematic reviews for selected USPSTF topics. It has helped the USPSTF integrate evidence across key questions addressed in systematic reviews, compare alternative screening methods and strategies, and weigh harms and benefits of interventions. However, modeling also requires additional expertise and resources. National Academy of Medicine standards for evidence-based recommendation development (27, 28) are already resource-intensive, and the addition of decision modeling further increases resource requirements and may prolong development of new or updated recommendations. The framework developed by the USPSTF (15) will help determine when to use modeling as a complement to systematic reviews and builds on the foundation laid by others outlining the use of decision modeling in the development of clinical practice recommendations (6, 24, 29–32).

More experience will help the USPSTF to further define strengths and limitations of modeling for recommendation development and more efficiently integrate systematic reviews and models. As the USPSTF gains experience with modeling analyses across a broader range of topics, the use of model-based estimates of net benefit may also facilitate comparison of benefits and harms across topics and recommendations. Such analyses may also be useful in discussions about the magnitude of benefit, and input from experts and stakeholders will help the USPSTF assess the usefulness of modeling for such comparisons.

From Stanford University, Stanford, California; Patient-Centered Outcomes Research Institute, Washington, DC; Kaiser Permanente Center for Health Research, Portland, Ore-

gon; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; VCU-Fairfax Family Medicine Residency, Fairfax, Virginia; University of California, San Francisco, San Francisco, California; University of Iowa, Iowa City, Iowa; Columbia University and Icahn School of Medicine at Mount Sinai, New York, New York; University of Georgia, Athens, Georgia; Harvard Medical School, Boston, Massachusetts; Group Health Research Institute, Seattle, Washington; Duke University, Durham, North Carolina; Yale University, New Haven, Connecticut; Health Partners Institute, Minneapolis, Minnesota; and University of Missouri, Columbia, Missouri.

Financial Support: This article is based in part on a report by the Kaiser Permanente Research Affiliates Evidence-based Practice Center under contract HHS-290-2007-10057-I to the Agency for Healthcare Research and Quality (AHRQ), Rockville, Maryland. AHRQ staff provided oversight for the project and assisted in external review of the companion draft report.

Disclosures: Dr. Henderson reports grants from AHRQ during the conduct of this work. Dr. Pignone reports having developed and revised decision models for preventive services (including aspirin to prevent cardiovascular disease and CRC screening) that are considered by the USPSTF. Dr. Maciosek reports grants from AHRQ during the conduct of this work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-2531.

Requests for Single Reprints: Reprints are available from the USPSTF Web site (www.uspreventiveservicestaskforce.org).

Current author addresses and author contributions are available at www.annals.org.

REFERENCES


**Current Author Addresses:**

Dr. Owens: Stanford University School of Medicine, 291 Campus Drive, Room LK3C02, Stanford, CA 94305.

Dr. Whitlock: Patient-Centered Outcomes Research Institute, 1828 L Street NW, Suite 900, Washington, DC 20036.

Dr. Henderson: Kaiser Permanente Center for Health Research, Kaiser Permanente Northwest, 3800 North Interstate Avenue, Portland, OR 97227.

Dr. Pignone: University of North Carolina at Chapel Hill, School of Medicine, 5045 Old Clinic Building, Chapel Hill, NC 27707.

Dr. Krist: VCU-Fairfax Family Medicine Residency, 3650 Joseph Siewick Drive, Suite 400, Fairfax, VA 22033.

Dr. Bibbins-Domingo: Department of General Internal Medicine, University of California, San Francisco, Box 1364, San Francisco, CA 94143.

Dr. Curry: University of Iowa, College of Public Health, 105 River Street, Iowa City, IA 52242.

Dr. Davidson: Columbia University Medical Center, 622 East 168th Street, New York, NY 10032.

Dr. Ebell: University of Georgia, B.S. Miller Hall Room 233, Health Sciences Campus, 101 Buck Road, Athens, GA 30602.

Dr. Gillman: Department of Population Medicine, Harvard Medical School, 401 Park Drive, Suite 401, Boston, MA 02215.

Dr. Grossman: Group Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101.

Dr. Kemper: Department of Pediatrics, Duke University, 4020 North Roxboro Street, Durham, NC 27704.

Dr. Kurth: Yale School of Nursing, Yale University West Campus, PO Box 27399, West Haven, CT 06516.

Dr. Maciosek: Health Partners Institute, PO Box 1524, Minneapolis, MN 55440.

Dr. Siu: Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1070, New York, NY 10029.

Dr. LeFevre: University of Missouri, School of Medicine, 1 Hospital Drive, Medical Sciences Building, Columbia, MO 65212.

**Author Contributions:**


Administrative, technical, or logistic support: J. Henderson, A.H. Krist, K.W. Davidson, A.E. Kurth.

Collection and assembly of data: J. Henderson, A.H. Krist.

**APPENDIX: U.S. PREVENTIVE SERVICES TASK FORCE MEMBERS**

Members of the USPSTF at the time this manuscript was finalized† are Kirsten Bibbins-Domingo, PhD, MD, MAS, Chair (University of California, San Francisco, San Francisco, California); David C. Grossman, MD, MPH, Co-Vice Chair (Group Health Research Institute, Seattle, Washington); Susan J. Curry, PhD, Co-Vice Chair (University of Iowa, Iowa City, Iowa); Karina W. Davidson, PhD, MASc (Columbia University, New York, New York); John W. Epling Jr., MD, MSeD (State University of New York Upstate Medical University, Syracuse, New York); Francisco A.R. García, MD, MPH (Pima County Department of Health, Tucson, Arizona); Matthew W. Gillman, MD, SM (Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts); Alex R. Kemper, MD, MPH, MS (Duke University, Durham, North Carolina); Alex H. Krist, MD, MPH (Fairfax Family Practice, Fairfax, and Virginia Commonwealth University, Richmond, Virginia); Ann E. Kurth, PhD, RN, MSN, MPH (Yale University, New Haven, Connecticut); C. Seth Landefeld, MD (University of Alabama at Birmingham, Birmingham, Alabama); Carol M. Mangione, MD, MSPH (University of California, Los Angeles, Los Angeles, California); William R. Phillips, MD, MPH (University of Washington, Seattle, Washington); Maureen G. Phipps, MD, MPH (Brown University, Providence, Rhode Island); and Michael P. Pignone, MD, MPH (University of North Carolina at Chapel Hill, Chapel Hill, North Carolina).

† For a list of current USPSTF members, go to www.uspreventiveservicestaskforce.org/Page/Name/our-members.